Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Changzhi Medical College; First Affiliated Hospital of Wenzhou Medical University; First Affiliated Hospital Xi'an Jiaotong University; Fudan University; Peking Union Medical College Hospital; Peking University First Hospital; Quanzhou First Hospital Affiliated to Fujian Medical University; Ruijin Hospital; Second Affiliated Hospital of Nantong University; Second Affiliated Hospital of Xi'an Jiaotong University; Second Affiliated Hospital, School of Medicine, Zhejiang University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Shanxi Provincial Cancer Hospital; Sir Run Run Shaw Hospital; Tang-Du Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The First Affiliated Hospital of Shanxi Medical University; The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital with Nanjing Medical University; The General Hospital of Eastern Theater Command; The Second Hospital of Anhui Medical University; Third Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; West China Hospital; Xiangya Hospital of Central South University; Xijing Hospital of Air Force Military Medical University; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Zhejiang University
• Treatments: Axitinib; Immune Checkpoint Inhibitors; Sunitinib

Criteria

Inclusion Criteria:

• Clinically diagnosed with renal cell carcinoma confirmed by pathology, including clear renal cell carcinoma and type I papillary renal cell carcinoma, type II papillary renal cell carcinoma, chromophobe renal cell carcinoma and renal cell carcinoma with sarcomatoid differentiation, etc

• Have distant metastasis

• metastatic RCC

• Eastern Cooperative Oncology Group 0 to 1

• No obvious abnormality was found in blood routine examination, coagulation and liver and kidney function

Exclusion Criteria:

• • Previously received systematic treatment

• Failure to obtain baseline tumor tissue / blood samples

• A history of infection with human immunodeficiency virus, or suffer from other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation, or have a history of organ transplantation

• A history of allergy to disease treatment drugs

• During lactation or pregnancy